Erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy
Tonelli M, Lloyd A, Lee H, Wiebe N, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Klarenbach S
Record ID 32007000765
English
Authors' recommendations:
The use of ESAs by patients with cancer led to clinically meaningful improvements in QoL and decreased the risk of blood transfusions. However, ESA use led to an increased risk of all-causemortality, a significant increase in the risk of serious adverse events, and cost-utility ratios that exceed commonly accepted standards for economic attractiveness. These considerations raisepotential safety concerns about the use of ESAs to manage anemia in patients with cancer and suggest that further review by payers and regulatory authorities may be advisable.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/907
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anemia
- Erythropoietin
- Hematopoietic Cell Growth Factors
- Neoplasms
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.